Novavax (NVAX) Receives ‘Analyst’ Rating

Novavax (NVAX) : Zacks Investment Research ranks Novavax (NVAX) as 4, which is a Sell recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 5 research analysts is 1.4, which indicates as a Strong Buy.

Novavax (NVAX) : The highest short term price target forecast on Novavax (NVAX) is $17 and the lowest target price is $6. A total of 5 equity analysts are currently covering the company. The average price of all the analysts is $12.98 with a standard deviation of $4.24.


Also, Citigroup maintains their rating on the shares of Novavax (NASDAQ:NVAX). The current rating of the shares is Buy. Equity Analysts at the Firm raises the price target to $12 per share from $10 per share. The rating by the firm was issued on July 28, 2016.

Novavax (NASDAQ:NVAX): After opening at $8.48, the stock dipped to an intraday low of $8.1 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $8.49 and the buying power remained strong till the end. The stock closed at $8.34 for the day, a gain of 0.36% for the day session. The total traded volume was 25,171,142. The stocks close on the previous trading day was $8.31.

Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.